ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

July 15, 2021

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) today announced that 75 research sites applied and have been invited to participate in a pilot project testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among clinical trial participants.

July 13, 2021

On July 13, 2021, the Centers for Medicare & Medicaid Services released its proposed rule for the 2022 Medicare Physician Fee Schedule and updates to the Quality Payment Program (QPP). The Association for Clinical Oncology (ASCO) is still analyzing the full proposal, but based on a preliminary analysis, key provisions for the cancer care community are included here. 

July 13, 2021

Today, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards, which provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence-based cancer care.

July 12, 2021

On July 9, 2021, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor.

July 9, 2021

On July 9, 2021, the Food and Drug Administration approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma US, Inc.).

July 6, 2021

In addition to the Association for Clinical Oncology’s (ASCO) advocacy at the federal level in Washington, DC, ASCO is also at work in state capitals advocating for improved patient access to high-quality, equitable cancer care at the state level.

July 2, 2021

The Department of Health and Human Services (HHS), the Department of Labor, the Department of the Treasury, and the Office of Personnel Management released an interim final rule with comment period (IFR), Requirements Related to Surprise Billing; Part I. This rule is the first of a series that will implement provisions of the No Surprises Act (NSA) signed into law as part of the 2021 COVID-19 relief bill.

July 1, 2021

On June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.

June 30, 2021

The Association for Clinical Oncology (ASCO) submitted comments to the Centers for Medicare & Medicaid Services in response to two cancer-related provisions in the 2022 Medicare Hospital Inpatient Prospective Payment System (IPPS) proposed rule. ASCO’s comments include responses to CMS’ Requests for Information (RFIs) on the transition to digital quality measures and health equity.

June 22, 2021

Delegates from the Association for Clinical Oncology (ASCO) participated in a Special Meeting of the American Medical Association’s (AMA) House of Delegates (HOD), where the HOD voted to approve two ASCO-backed resolutions.

June 22, 2021

In a joint position statement, ASCO and Friends of Cancer Research say individuals with cancer or a history of cancer should be eligible for clinical trials—including COVID-19 vaccine trials—unless there is safety justification for exclusion.

June 17, 2021

The U.S. Department of Health and Human Services (HHS) released revised reporting requirements for recipients of Provider Relief Fund (PRF) payments. Updates include expanding the amount of time providers will have to report information, efforts to reduce burdens on smaller providers, and extending key deadlines for expending PRF payments for recipients who received payments after June 30, 2020.

June 16, 2021

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation.

June 16, 2021

On June 16, 2021, the Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

June 8, 2021

The COVID-19 pandemic has profoundly interrupted delivery of key preventive services, resulting in many adolescents missing routine human papillomavirus (HPV) vaccine doses. In response, the American Society of Clinical Oncology (ASCO) and nearly 80 National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation’s health care systems, physicians, parents and children, and young adults to get HPV vaccination back on track.

Pages